Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DOUBLE PRO-TECT Alport: a Confirmatory, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Dapagliflozin on the Progression of Chronic Kidney Disease in Adolescents and Young Adult Patients with Alport Syndrome

NCT05944016 is registered in ClinicalTrials.gov with University Hospital Goettingen as lead sponsor.

NCT NCT05944016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05944016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DOUBLE PRO-TECT Alport: a Confirmatory, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Dapagliflozin on the Progression of Chronic Kidney Disease in Adolescents and Young Adult Patients with Alport Syndrome
Lead sponsor
University Hospital Goettingen
Phase
Phase 3
Overall status
Recruiting
Start date
March 25, 2024
Completion date
December 31, 2026
Enrollment
102 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney failure in children and young adults